January 23, 2018
The Federal Circuit on Tuesday upheld a Patent Trial and Appeal Board decision invalidating a Johnson & Johnson patent on the blockbuster autoimmune disease drug Remicade for double patenting, in a win for Pfizer Inc., which launched a biosimilar version in 2016.
October 03, 2017
A Johnson & Johnson subsidiary urged the Federal Circuit on Tuesday to reverse a decision invalidating a patent on its blockbuster autoimmune disease drug Remicade for double-patenting, saying the finding conflicts with a 1994 law changing the length of patent terms.